EQS-News: TVM Life Science Management GmbH
/ Key word(s): Conference
TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA '24 EMERGING MEDTECH SUMMIT 2024 TVM and Portfolio Companies Showcase Transformative Partnerships and Industry Trends in Panel discussions and Presentations Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) - TVM Capital Life Science ("TVM"), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA '24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place March 18-22, 2024, in Dana Point, California, USA. "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction. As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care. We look forward to engaging with fellow industry leaders at this year's Emerging Medtech Summit and to exploring new opportunities with innovative entrepreneurs that could further enrich our portfolio," said Dr. Luc Marengère, Managing Partner. TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages TVM's strategic relationship with global pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on innovative businesses from North America or the EU working to transform medical practice with their groundbreaking devices and technologies. Dr. Sascha Berger, General Partner, emphasized: "Amidst the current hype surrounding artificial intelligence, it's highly gratifying to participate in investments that embody the true transformative potential of AI in healthcare. These technologies have the capability to revolutionize how healthcare is delivered, making it accessible and personalized. Medtech and AI present exciting opportunities for investors who are willing to navigate this rapidly evolving landscape. Our successful track record of collaborations in medical technologies underscores our commitment to foster partnerships and add value to cutting edge innovative ventures." TVM Participation:
The following companies from TVM's medtech commercial-stage portfolio will present at the summit:
About TVM Capital Life Science TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm's strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives. For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.
13.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
1857975 13.03.2024 CET/CEST
